Navigation Links
Brain cell discovery could open doors to targeted cancer therapies
Date:4/11/2014

Fresh insights into the processes that control brain cell production could pave the way for treatments for brain cancer and other brain-related disorders.

Scientists have gained new understanding of the role played by a key molecule that controls how and when nerve and brain cells are formed a process that allows the brain to develop and keeps it healthy. Their findings could help explain what happens when cell production goes out of control, which is a fundamental characteristic of many diseases including cancer.

Researchers have focused on a RNA molecule, known as miR-9, which is linked to the development of brain cells, known as neurons and glial cells. They have shown that a protein called Lin28a regulates the production of miR-9, which in turn controls the genes involved in brain cell development and function.

Scientists carried out lab studies of embryonic cells, which can develop into neurons, to determine how Lin28a controls the amount of miR-9 that is produced.

They found that in embryonic cells, Lin28a prevents production of miR-9 by triggering the degradation of its precursor molecule. In developed brain cells, Lin28a is no longer produced, which enables miR-9 to accumulate and function. In cancer cells, Lin28a production is re-established, and as a result this natural process is disrupted.

Researchers used a series of lab tests to unravel the complex processes that are directed by the Lin28a protein. They say further studies could help explain fully the role of Lin28a and miR-9 in brain development, and pave the way to the development of novel therapies.

Dr Gracjan Michlewski of the School of Biological Sciences, who led the study, said: "Understanding more of the complex science behind the fundamental processes of cell development will helps us learn more about what happens when this goes wrong and what might be done to prevent it."


'/>"/>

Contact: Catriona Kelly
Catriona.Kelly@ed.ac.uk
44-131-651-4401
University of Edinburgh
Source:Eurekalert

Page: 1

Related medicine news :

1. Deep, integrated genomic analysis re-classifies lower-grade brain tumors
2. UCSF launches groundbreaking online registry to drive brain disease research
3. DNA modifications measured in blood signal related changes in the brain
4. Lipid levels during prenatal brain development impact autism: York U study
5. Fruitfly study: Epilepsy drug target implications for sleep disruption in brain disorders
6. Using your loaf to fight brain disease
7. Anesthetic technique important to prevent damage to brain
8. Adult cancer drugs show promise against an aggressive childhood brain tumor
9. The Brain & Behavior Research Foundation awards $4 million in NARSAD Grants
10. USF study finds stem cell combination therapy improves traumatic brain injury outcomes
11. US headache sufferers get $1 billion worth of brain scans each year, U-M study finds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements owned by ... to enhance the health of felines. The formula is all-natural and is made from ... the PawPaws Cat Kidney Support Supplement Soft Chews are Astragalus Root Extract ...
(Date:6/26/2016)... Clarkston, Michigan (PRWEB) , ... June 26, 2016 ... ... respect to fertility once they have been diagnosed with endometriosis. These women need ... but they also require a comprehensive approach that can help for preservation of ...
(Date:6/25/2016)... ... , ... Austin residents seeking Mohs surgery services, can now turn to Dr. ... Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization to include ... in Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... "With 30 ... their specific project," said Christina Austin - CEO of Pixel Film Studios. , ... and all within Final Cut Pro X . Simply select a ProHand generator ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. ... his M.D from the David Geffen School of Medicine at UCLA. He trained in ... to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that it ... (procalcitonin) assay as a dedicated testing solution for people ... Roche is the first IVD company in the U.S ... assessment and management. PCT is a sepsis-specific ... blood can aid clinicians in assessing the risk of ...
(Date:6/23/2016)... 23, 2016 Capricor Therapeutics, ... a biotechnology company focused on the discovery, development ... patient enrollment in its ongoing randomized HOPE-Duchenne clinical ... 50% of its 24-patient target. Capricor expects the ... quarter of 2016, and to report top line ...
(Date:6/23/2016)... June 23, 2016 Bracket , a leading ... next generation clinical outcomes platform, Bracket eCOA (SM) 6.0, ... June 26 – 30, 2016 in Philadelphia ... Clinical Outcome Assessment product of its kind to fully integrate ... Bracket eCOA 6.0 is a flexible platform for electronic ...
Breaking Medicine Technology: